AnalystBook Research · Company Intelligence

Vaxcyte, Inc.

PCVXNasdaq

Built from Vaxcyte, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score 7.59 safe zoneOK

Leadership changes

From Vaxcyte, Inc.'s own filings, the day they're filed.

  • John Markels · director · appointmenteff. 2026-07-16
  • Heath Lukatch · Directors · departureeff. 2026-07-16
  • Moncef Slaoui · director · appointmenteff. 2026-06-17

Latest filings

  • 8-K · Company announcement2026-09-03
  • 8-K · Company announcement2026-08-05
  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-07-15
  • 8-K · Company announcement2026-06-23
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Vaxcyte, Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Vaxcyte, Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.